These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 20149590)

  • 21. Drotrecogin alfa (activated) in patients with severe sepsis presenting with purpura fulminans, meningitis, or meningococcal disease: a retrospective analysis of patients enrolled in recent clinical studies.
    Vincent JL; Nadel S; Kutsogiannis DJ; Gibney RT; Yan SB; Wyss VL; Bailey JE; Mitchell CL; Sarwat S; Shinall SM; Janes JM
    Crit Care; 2005 Aug; 9(4):R331-43. PubMed ID: 16137345
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early drotrecogin alpha (activated) administration in severe sepsis is associated with lower mortality: a retrospective analysis of the Canadian ENHANCE cohort.
    Hodder RV; Hall R; Russell JA; Fisher HN; Lee B
    Crit Care; 2009; 13(3):R78. PubMed ID: 19457240
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plasma brain natriuretic peptide and troponin levels in severe sepsis and septic shock: relationships with systolic myocardial dysfunction and intensive care unit mortality.
    Klouche K; Pommet S; Amigues L; Bargnoux AS; Dupuy AM; Machado S; Serveaux-Delous M; Morena M; Jonquet O; Cristol JP
    J Intensive Care Med; 2014; 29(4):229-37. PubMed ID: 23753226
    [TBL] [Abstract][Full Text] [Related]  

  • 24. International INtegrated Database for the Evaluation of severe sePsis and drotrecogin alfa (activated) THerapy: component trials and statistical methods for INDEPTH.
    Sashegyi A; Trzaskoma BL; Nelson DR; Williams MD; Macias W
    Curr Med Res Opin; 2006 May; 22(5):1001-12. PubMed ID: 16709322
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum level of cardiac troponin I in pediatric patients with sepsis or septic shock.
    Oliveira NS; Silva VR; Castelo JS; Elias-Neto J; Pereira FE; Carvalho WB
    Pediatr Crit Care Med; 2008 Jul; 9(4):414-7. PubMed ID: 18843251
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic value of plasma N-terminal pro-brain natriuretic peptide in patients with severe sepsis.
    Brueckmann M; Huhle G; Lang S; Haase KK; Bertsch T; Weiss C; Kaden JJ; Putensen C; Borggrefe M; Hoffmann U
    Circulation; 2005 Jul; 112(4):527-34. PubMed ID: 16027260
    [TBL] [Abstract][Full Text] [Related]  

  • 27. International integrated database for the evaluation of severe sepsis (INDEPTH): clinical evaluation committee report on the safety of drotrecogin alfa (activated) therapy.
    Dhainaut JF;
    Curr Med Res Opin; 2008 Apr; 24(4):1187-97. PubMed ID: 18348744
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ENHANCE: results of a global open-label trial of drotrecogin alfa (activated) in children with severe sepsis.
    Goldstein B; Nadel S; Peters M; Barton R; Machado F; Levy H; Haney DJ; Utterback B; Williams MD; Giroir BP
    Pediatr Crit Care Med; 2006 May; 7(3):200-11. PubMed ID: 16575354
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiac troponin I levels are a risk factor for mortality and multiple organ failure in noncardiac critically ill patients and have an additive effect to the APACHE II score in outcome prediction.
    Wu TT; Yuan A; Chen CY; Chen WJ; Luh KT; Kuo SH; Lin FY; Yang PC
    Shock; 2004 Aug; 22(2):95-101. PubMed ID: 15257080
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pathophysiologic mechanisms of persistent cardiac troponin I elevation in stabilized patients after an episode of acute coronary syndrome.
    Eggers KM; Lagerqvist B; Oldgren J; Venge P; Wallentin L; Lindahl B
    Am Heart J; 2008 Sep; 156(3):588-94. PubMed ID: 18760145
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ADDRESS (ADministration of DRotrecogin alfa [activated] in Early stage Severe Sepsis) long-term follow-up: one-year safety and efficacy evaluation.
    Laterre PF; Abraham E; Janes JM; Trzaskoma BL; Correll NL; Booth FV
    Crit Care Med; 2007 Jun; 35(6):1457-63. PubMed ID: 17452935
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Systemic host responses in severe sepsis analyzed by causative microorganism and treatment effects of drotrecogin alfa (activated).
    Opal SM; Garber GE; LaRosa SP; Maki DG; Freebairn RC; Kinasewitz GT; Dhainaut JF; Yan SB; Williams MD; Graham DE; Nelson DR; Levy H; Bernard GR
    Clin Infect Dis; 2003 Jul; 37(1):50-8. PubMed ID: 12830408
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biomarker response to drotrecogin alfa (activated) in children with severe sepsis: results from the RESOLVE clinical trial*.
    Dalton HJ; Carcillo JA; Woodward DB; Short MA; Williams MD
    Pediatr Crit Care Med; 2012 Nov; 13(6):639-45. PubMed ID: 22791090
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A prospective, observational study of Xigris Use in the United States (XEUS).
    Steingrub JS; Cheatham ML; Woodward B; Wang HT; Effron MB;
    J Crit Care; 2010 Dec; 25(4):660.e9-16. PubMed ID: 20435433
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A registry of patients treated with drotrecogin alfa (activated) in Belgian intensive care units--an observational study.
    Vincent JL; Laterre PF; Decruyenaere J; Spapen H; Raemaekers J; Damas F; Rogiers P; Sartral M; Haentjens T; Nelson D; Janes J
    Acta Clin Belg; 2008; 63(1):25-30. PubMed ID: 18386762
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of an integrated clinical trial database to evaluate the effect of timing of drotrecogin alfa (activated) treatment in severe sepsis.
    Vincent JL; O'Brien J; Wheeler A; Wittebole X; Garg R; Trzaskoma BL; Sundin DP
    Crit Care; 2006; 10(3):R74. PubMed ID: 16684364
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of enrollment sequence effect on observed outcomes in the ADDRESS and PROWESS studies of drotrecogin alfa (activated) in patients with severe sepsis.
    Laterre PF; Macias WL; Janes J; Williams MD; Nelson DR; Girbes AR; Dhainaut JF; Abraham E
    Crit Care; 2008; 12(5):R117. PubMed ID: 18786266
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drotrecogin alfa (activated): real-life use and outcomes for the UK.
    Rowan KM; Welch CA; North E; Harrison DA
    Crit Care; 2008; 12(2):R58. PubMed ID: 18430215
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictors of hospital mortality for patients with severe sepsis treated with Drotrecogin alfa (activated).
    Micek ST; Isakow W; Shannon W; Kollef MH
    Pharmacotherapy; 2005 Jan; 25(1):26-34. PubMed ID: 15767217
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Static and dynamic assessment of biomarkers in surgical patients with severe sepsis.
    Lowry SF; Awad S; Ford H; Cheadle W; Williams MD; Qualy RL; McCollam JS; Bates BM; Fry DE;
    Surg Infect (Larchmt); 2004; 5(3):261-8. PubMed ID: 15684797
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.